Juggling Geographic Commercialization Priorities

Commercializing a pharmaceutical asset in one country is hard enough. Doing it…

pipeline-medical-affairs-an-orchestra-not-a-horse-race

Medical Affairs: An Orchestra, Not a Horse Race

Every horse race has a starting bell, a push to move as fast as possible, and a…

Three Big Mistakes

Over the past 20 years, The NemetzGroup has been involved in the launch of more…

The Truth about Teams

When it comes to team performance and adherence to “best practices,” what works…

Optimizing Your Essential Commercialization Teams

For those of you following closely (thank you!), you may recall that in an earlier e-conversation — 21st Century Commercialization — More than a…

DNA molecules banner

Are Your Assumptions Serving You Well?

Ah, June, the season of life transitions — weddings, graduations, school progression and, with the year nearly half over, a reminder to reflect on…

The Future Is Now

The Future of Biopharma Commercialization Is Now

Back in the early 2000s, I was head of commercial strategy at Millennium Pharmaceuticals in Cambridge, Massachusetts. I remember saying to then CEO,…

Tales from the Healthcare Front Lines

Each month, you have given our team permission to communicate our views on the biopharma industry, its leadership, and overall commercialization of…

Does Boston Biotech Have a Career Navigation Problem?

For those of us who have been in the industry since pre-DRG days, and have the wisdom and experience across the industry, there are many…